Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Obesity causes variable effects on Phase I enzymes due to fatty liver infiltration. While some Phase I enzymes show increased activity influenced by fatty acids and ethanol, CYP3A4 activity typically decreases in obese patients. These changes significantly alter how drugs metabolized by Phase I enzymes are processed, affecting drug clearance rates and therapeutic outcomes.

Obesity enhances the activity of uridine diphosphate glucuronosyltransferase (UGT), a major Phase II conjugation enzyme. This increased enzyme activity results in faster drug clearance compared to non-obese patients. The enhanced Phase II metabolism in obesity reflects altered metabolic capacity, requiring clinicians to consider adjusted dosing strategies for drugs dependent on UGT metabolism.

High-extraction drugs show increased clearance in obese individuals, indicating enhanced liver blood flow. This increased hepatic perfusion, combined with altered enzyme activities, affects how rapidly these drugs are eliminated. Understanding these changes is critical for optimizing drug dosing in obese populations to maintain therapeutic efficacy.

Obesity alters multiple renal elimination processes including glomerular filtration, tubular secretion, and tubular reabsorption, generally increasing drug clearance. For example, lithium demonstrates lower tubular reabsorption in obese patients, leading to enhanced clearance. These renal changes require careful monitoring and potential dose adjustments for renally eliminated drugs in obese populations.

Nonalcoholic fatty liver disease (NAFLD) develops from fatty infiltration of the liver in obese patients, modifying both Phase I and Phase II enzyme activities. This hepatic condition disrupts normal drug metabolism pathways, reducing the activity of certain enzymes like CYP3A4 while potentially enhancing others. NAFLD represents a key mechanism linking obesity to altered pharmacokinetics.

Multiple CYP enzymes exhibit variable activity changes in obesity, including CYP2E1, which increases due to metabolic demands of fatty acids and ketones, while CYP2D6, CYP1A2, CYP2C9, and CYP2C19 show inconsistent changes. These variable responses across different CYP enzymes complicate drug metabolism prediction in obese patients and necessitate individualized pharmacokinetic assessment.

Enzyme activities in obese patients are influenced by genetic polymorphisms combined with metabolic factors including fatty acids, ethanol, and ketones. These substances accumulate at higher levels in obesity and interact with genetic variations to modulate Phase I and II enzyme function. This complex interplay requires nuanced understanding of individual patient factors for optimal drug therapy.